Use of tranexamic acid for trauma patients
Reading File
Finding Sources
Searching PubMed
"tranexamic acid"[MeSH Terms] AND "wounds and injuries"[MeSH Terms]
Finding Sources
Reading File
Reading File
Reading File
Reading Article
PMID: 40842057
Reading File
Reading Article
PMID: 37999653
Reading Article
PMID: 40956301
Excellent - I now have comprehensive information from textbooks and current guidelines. Let me compile a thorough answer.
Tranexamic Acid (TXA) in Trauma
Mechanism of Action
TXA is a synthetic antifibrinolytic agent. It inhibits lysine binding sites on plasminogen, which reduces plasmin activity. Plasmin normally cleaves fibrin clots, so by blocking this step, TXA preserves clot integrity and limits hemorrhage. This makes it particularly relevant in trauma, where tissue injury triggers a rapid early fibrinolytic phase of trauma-induced coagulopathy (TIC). - Barash Clinical Anesthesia, p. 4514; Tintinalli's Emergency Medicine, p. TXA section
Rationale in Trauma
After major trauma, patients frequently enter a state of hyperfibrinolysis - fibrin clots are broken down faster than they can form. This is part of the coagulopathy of trauma (the "lethal triad" of acidosis, hypothermia, and coagulopathy). TXA addresses the fibrinolytic component directly.
However, fibrinolytic states in trauma are heterogeneous:
- Hyperfibrinolysis (~18% of patients): high mortality (~44%) - TXA most clearly beneficial
- Physiologic fibrinolysis (~18%): low mortality (~3%)
- Fibrinolytic shutdown (~64%): mortality ~17% - TXA use here is more controversial, may worsen outcomes
This means blind administration to all trauma patients has been questioned. - Barash Clinical Anesthesia, p. 4514
Landmark Evidence
| Trial | Key Finding |
|---|---|
| CRASH-2 (>20,000 patients, multicenter RCT) | TXA reduced all-cause mortality and death from bleeding; no increase in vascular occlusion; benefit only within 3 hours of injury |
| MATTERs (896 military trauma patients) | Patients receiving TXA had lower mortality despite being more severely injured; greatest benefit in those receiving >10 units PRBCs |
| CRASH-3 (>12,000 TBI patients) | In mild-to-moderate TBI, TXA reduced TBI-related death (RR 0.78, 95% CI 0.64-0.95); patients with reactive pupils especially benefited |
| PATCH-Trauma (prehospital RCT) | Investigated prehospital TXA in severe trauma |
Dosing
The standard regimen used across guidelines and trials:
- Loading dose: 1 g IV over 10 minutes
- Maintenance dose: 1 g IV over 8 hours
An alternative regimen (2 g IV as a single infusion/slow push) is also accepted for prehospital settings. The 2025 NAEMSP/ACEP/ACS-COT joint position statement notes neither dosing scheme has been definitively proven superior.
- Bailey and Love's Surgery, p. 8081; Tintinalli's EM, p. 1548
Timing - Critical Window
This is the most important clinical consideration. The window for TXA is narrow:
- Within 1 hour of injury: Reduces relative risk of death from bleeding by 32%
- 1-3 hours after injury: Reduces relative risk by 21%
- Beyond 3 hours: Administration is contraindicated - potentially harmful and associated with increased mortality
TXA should therefore be given prehospitally (by paramedics in the field) whenever possible, before the patient arrives at a trauma center. - Tintinalli's EM, p. 1546-1548
Who Gets It? (Patient Selection)
Administer TXA to trauma patients who have:
- Suspected significant hemorrhage, AND
- SBP <110 mmHg, OR pulse >110/min, OR clinical signs of hemorrhagic shock
- Administration must be feasible within the 3-hour window
The 2025 EAST Practice Management Guideline (Dumas et al.) conditionally recommends TXA in both prehospital and in-hospital settings, including patients with severe hypotension (SBP ≤90 mmHg).
The 2025 NAEMSP/ACEP/ACS-COT joint statement specifically recommends prehospital TXA for adult trauma patients with hemorrhagic shock, administered after lifesaving interventions.
Special Populations
Traumatic Brain Injury (TBI)
CRASH-3 showed benefit in mild-to-moderate TBI specifically - TBI-related death reduced (RR 0.78). Patients with reactive pupils had the strongest benefit. Patients with fixed/dilated pupils did not benefit. TXA should not be given to TBI patients who also have major extracranial bleeding without accounting for both injuries. A 2024 meta-analysis on TBI (PMID 38387502) also supports this.
Pediatric Trauma
Evidence is limited. The 2025 joint position statement notes dosing has not been standardized in children. If used, administer within 3 hours of injury.
Burns
A 2023 systematic review (PMID 37268542) found TXA reduces blood loss in burn surgery, though evidence quality varies.
Safety Profile
Across major trials and a 2024 bias-adjusted meta-analysis of RCTs (Fouche et al., Ann Emerg Med 2024, PMID 37999653):
- No significant increase in myocardial infarction, stroke, pulmonary embolism, or vascular occlusion
- No increase in seizures at the standard 1 g trauma dose (seizures are a dose-dependent risk at the much higher cardiac surgery doses)
- TXA appears safe in hemorrhagic shock patients
The 2024 meta-analysis reported an 11% reduction in 1-month mortality (OR 0.89, 95% CI 0.84-0.95; NNT = 61) and a 24% reduction in 24-hour mortality (OR 0.76, 95% CI 0.65-0.88).
Context in Damage Control Resuscitation
TXA is one component of a broader resuscitation strategy. It should be used alongside:
- Massive transfusion protocol (1:1:1 ratio of PRBCs:FFP:platelets)
- Hemorrhage control (surgical or endovascular)
- Correction of acidosis and hypothermia
- Calcium supplementation (to counteract citrate-chelation from blood products)
- Viscoelastic testing (TEG/ROTEM) to guide coagulation product selection
Key Summary Points
| Point | Detail |
|---|---|
| Mechanism | Antifibrinolytic - inhibits plasminogen binding |
| Dose | 1 g IV over 10 min, then 1 g over 8 hours |
| Time window | Must be within 3 hours of injury; earlier is better |
| Indication | Hemorrhagic shock / suspected significant bleeding |
| Contraindication | >3 hours post-injury (harmful); fibrinolytic shutdown state |
| Benefit in TBI | Mild-to-moderate TBI with reactive pupils |
| Safety | No significant thrombotic risk at trauma doses |
| Setting | Can be given prehospitally (preferred) or in-hospital |
Current guideline support (2025): Both EAST and the NAEMSP/ACEP/ACS-COT joint position statement conditionally recommend TXA for trauma patients at risk of hemorrhage, emphasizing early prehospital use. The optimal dose (1 g+1 g vs. 2 g single dose) remains under investigation.
This is a shared conversation. Sign in to Orris to start your own chat.